Skip to main content
. 2009 Jul 1;284(36):24553–24567. doi: 10.1074/jbc.M109.019364

FIGURE 1.

FIGURE 1.

A, recombinant human fibulin-4 and -5. Domain structures of full-length fibulin-4 (F4), C-terminally truncated fibulin-4 (tF4), the N-terminal half of fibulin-4 (nF4), and the five central cbEGFs (eF4) are shown, with a key of the domains and N-glycosylation sites. Also shown are the domain structures of full-length fibulin-5 (F5) with the sites of the two cutis laxa mutations (F5C217R and F5S227P) and domain pair fragments. Details of the domains are given (see key). For SDS-PAGE analysis of recombinant fibulins, see supplemental Fig. S1A. B, recombinant human fibrillin-1. Domain structures of full-length fibrillin-1, a C-terminally truncated two-third fragment of fibrillin-1 (tFib-1), overlapping fragments, and N-terminal deletion fragments are shown, with a key of the domains and N-glycosylation sites. All fragments have been described (39, 55) except for tFib-1 (for mass spectrometry of tFib-1, see supplemental Fig. S2B). Details of the domains are given (see key), and the colors indicate overlapping recombinant fragments. For SDS-PAGE analysis of recombinant tFib-1, see supplemental Fig. S1B. C, recombinant human LOX. The molecular arrangement of full-length human LOX is shown. BMP-1, position of the bone morphogenetic protein-1 cleavage site. For SDS-PAGE analysis of recombinant LOX, see supplemental Fig. S1C. EGF, epidermal growth factor.